Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma.

Andres Chang, Jackelyn B Payne, Pamela B Allen, Jean L Koff, Rafi Ahmed, Christopher R Flowers, Robert A Bednarczyk
Author Information
  1. Andres Chang: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA. Electronic address: andres.chang@emory.edu.
  2. Jackelyn B Payne: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
  3. Pamela B Allen: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
  4. Jean L Koff: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
  5. Rafi Ahmed: Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA.
  6. Christopher R Flowers: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
  7. Robert A Bednarczyk: Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA.

Abstract

INTRODUCTION: Influenza infection causes significant morbidity and mortality in patients with cancer, and annual influenza vaccination for individuals with cancer is recommended. We sought to examine the documentation rate of influenza vaccine administration, refusal, or counseling in the first year after diagnosis of diffuse large B cell lymphoma (DLBCL) for patients across 3 hospitals in 2 health care systems.
PATIENTS AND METHODS: Documentation of vaccine administration, refusal, or counseling by physicians, advanced practice providers, or nursing staff during the first period of influenza vaccine availability after diagnosis (August to April) was assessed in medical records of patients diagnosed with DLBCL between February 2015 and October 2017 who presented to Emory St. Joseph Hospital (community hospital), Winship Cancer Institute of Emory University (academic medical center), or Grady Memorial Hospital (county hospital).
RESULTS: Of the 57% (61/107) of newly diagnosed patients with DLBCL who had vaccine-related documentation, 43% refused vaccination. Counseling was not documented for any patient. Inpatient nursing performed 75% of all documentation. Primary oncologists documented vaccination in 4% of all cases.
CONCLUSION: Despite the limited immunization documentation and high refusal rates observed in this study, the influenza vaccine refusal rate was lower than the average for the United States, the state of Georgia, and the previous studies of patients with cancer. Although routine outpatient vaccination occurs, improvements in screening, strategies for sharing patient vaccine-related information, and counseling of patients who refuse the vaccine are needed. Further work is also needed to determine the effectiveness of influenza vaccination in patients receiving anti-cancer therapy.

Keywords

References

  1. JCI Insight. 2017 Jun 15;2(12): [PMID: 28614800]
  2. Prev Med Rep. 2018 Jun 18;11:131-138 [PMID: 30003011]
  3. MMWR Recomm Rep. 2017 Aug 25;66(2):1-20 [PMID: 28841201]
  4. Am J Prev Med. 2016 Jun;50(6):797-808 [PMID: 26847663]
  5. Blood. 2012 Aug 30;120(9):1954-7 [PMID: 22936740]
  6. Am J Prev Med. 2018 Feb;54(2):299-315 [PMID: 29362167]
  7. Leuk Lymphoma. 2011 Sep;52(9):1736-41 [PMID: 21663502]
  8. J Immunol. 2011 May 15;186(10):6044-55 [PMID: 21498665]
  9. Blood. 2011 Dec 22;118(26):6769-71 [PMID: 22058114]
  10. Am J Prev Med. 2016 Jan;50(1):e15-e26 [PMID: 26238603]
  11. Lancet Infect Dis. 2009 Aug;9(8):493-504 [PMID: 19628174]
  12. CA Cancer J Clin. 2017 Sep;67(5):398-410 [PMID: 28753241]
  13. J Natl Compr Canc Netw. 2016 Jul;14(7):882-913 [PMID: 27407129]
  14. Ann Oncol. 2008 Sep;19(9):1658 [PMID: 18662953]

Grants

  1. K01 AI106961/NIAID NIH HHS
  2. K24 CA208132/NCI NIH HHS
  3. T32 CA160040/NCI NIH HHS
  4. U01 CA195568/NCI NIH HHS

MeSH Term

Adult
Aged
Aged, 80 and over
Documentation
Female
Georgia
Humans
Influenza Vaccines
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
Retrospective Studies
Vaccination
Vaccination Refusal
Young Adult

Chemicals

Influenza Vaccines

Word Cloud

Created with Highcharts 10.0.0patientsvaccineinfluenzavaccinationdocumentationrefusalDLBCLInfluenzacancercounselingrateadministrationfirstdiagnosisBlymphomaDocumentationnursingmedicaldiagnosedEmoryHospitalhospitalvaccine-relateddocumentedpatientscreeningneededINTRODUCTION:infectioncausessignificantmorbiditymortalityannualindividualsrecommendedsoughtexamineyeardiffuselargecellacross3hospitals2healthcaresystemsPATIENTSANDMETHODS:physiciansadvancedpracticeprovidersstaffperiodavailabilityAugustAprilassessedrecordsFebruary2015October2017presentedStJosephcommunityWinshipCancerInstituteUniversityacademiccenterGradyMemorialcountyRESULTS:57%61/107newly43%refusedCounselingInpatientperformed75%Primaryoncologists4%casesCONCLUSION:DespitelimitedimmunizationhighratesobservedstudyloweraverageUnitedStatesstateGeorgiapreviousstudiesAlthoughroutineoutpatientoccursimprovementsstrategiessharinginformationrefuseworkalsodetermineeffectivenessreceivinganti-cancertherapyVaccinationRatesFirstYearDiagnosisDiffuseLargeCellLymphomaFluNon-HodgkinVaccine

Similar Articles

Cited By